On May 15, 2026, FCPM III Services B.V. reported a sale of 818,460 shares of Dyne Therapeutics (NASDAQ:DYN), an estimated $14.11 million trade based on quarterly average pricing.
What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, FCPM III Services B.V. reduced its position in Dyne Therapeutics by 818,460 shares
The estimated transaction value was $14.11 million, calculated using the mean unadjusted closing price for the first quarter of 2026. The net position value in Dyne Therapeutics shifted by $22.65 million over the period, reflecting both trading and price changes. What else to know – This was a sell; Dyne Therapeutics now comprises 11.8% of the fund’s 13F reportable AUM. – Top holdings after the filing: – NASDAQ: NAMS: $294.46 million (41.2% of AUM) – NASDAQ: DYN: $84.20 million (11.8% of AUM) – NASDAQ: VOR: $73.45 million (10.3% of AUM) – NASDAQ: ENGN: $65.60 million (9.2% of AUM) – NASDAQ: MPLT: $65.59 million (9.2% of AUM) – – As of May 14, 2026, Dyne Therapeutics shares were priced at $18.28, up 56% over the past year and outperforming the S&P 500 by about 28 percentage points.
Company Overview Company Snapshot – Dyne Therapeutics develops therapeutics for genetically driven muscle diseases, including myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, leveraging its proprietary FORCE platform. – The firm operates a biotechnology business model focused on research and development of disease-modifying therapies, with revenue potential tied to future regulatory approvals and commercialization. – It targets patients with rare skeletal, cardiac, and metabolic muscle diseases, primarily in the United States, with a focus on unmet medical needs in the neuromuscular disease segment. Dyne Therapeutics is a biotechnology company specializing in the development of therapeutics for rare, genetically driven muscle diseases. The company leverages its FORCE platform to advance a…